Real-world usage and effectiveness of Uroletics® in patients with prostate cancer

Real-world usage and effectiveness of Uroletics® in patients with prostate cancer - Real_Uroletics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00037900

Enrollment

200

Registered

2026-01-26

Start date

2026-02-02

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C61

Interventions

Group 1: This is a single-arm, retrospective study. The app is used in routine care.

Eligibility

Sex/Gender

Male

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Men with prostate cancer (ICD10-GM-2025: C61) who have registered in the Uroletics® app not later than 4 weeks after radical prostatectomy. • Documented date of radical prostatectomy. • Data privacy consent.

Exclusion criteria

Exclusion criteria: Patients without at least one additional observation after app registration.

Design outcomes

Primary

Measure	Time frame
Time to continence and continence rate	—

Secondary

Measure	Time frame
• Health-related quality of life (HRQoL) up to 12 weeks after radical prostatectomy • Erectile function up to 12 weeks after radical prostatectomy • General QoL up to 12 weeks after radical prostatectomy	—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026